- Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.
- Marques-Vidai P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the "rule of halves" still valid? J Hum Hypertens 1997; 11: 213-20.
- Hosie J, Wilklund I. Managing hypertension in general practice: can do we better? J Hum Hypertens 1995; 9: S15-18.
- Mancia G, Sega R, Miles! C, Cesana G, Zanchetti A. Blood pressure control in the hypertensive population. Lancet 1997; 349: 454-57.
- Blood Pressure Lowering Treatment Trialisf Collaboration. Effects of ACE inhibitors, calcium channel blockers, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955-64.
- van Zwieten PA, Mancia G. Third generation calcium antagonists: further developments. Blood Press 1996; 5: 376-77.
- Guarneri L, Sironi G, Angelico P, et al. In vitro and in vivo vascular selectivity of Lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997; 29 Suppl 1: S25-32.
- van Zwieten PA. The pharmacological properties of lipophilic calcium antagonists. Blood Press 1998; 7 Suppl 2:5-9.
- Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Exp Opin Invest Drugs 1999; 8: 1043-62.
- Herbette LG, Vecchiarelfi M, Leonardi A. Lercanidipine: Short plasma half-life, long duration of action: a molecular model to rationalize its pharmacokinetic properties. J Cardiovasc Pharmacol 1997; 29 Suppl 1: S19-24.
- Omboni S, Zanchetti A, on behalf of the Multicenter Study Investigators. Antihypertensive efficacy of Lercanidipine 2,5,5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure. J Hypertens 1998; 16: 1831-8.
- Macchiarulo C, Fieri R, Mitolo DC, Pirrelli A. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour blood pressure recordings. Curr Ther Res Clin Exp 2001; 62: 236-53.
- Ambrosioni E, Circo A. Activity of Lercanidipine administered in single and repeated doses once daily as monitored over 24 hours in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1997; 29 Suppl 2: S16-20.
- Testa R, Leonardi A, Tajana A, Riscassi E, Maggliocca R, Sartani A. Lercanidipine (Rec 15/2375): a novel 1,4-dihydropyridine calcium antagonist for hypertension. Cardiovasc Drug Rev 1997; 15: 187-219.
- Circo A. Active dose findings for Lercanidipine in a doubleblind placebo-controlled design in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1997; 29 Suppl 2: S22-6.
- McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs 2000; 60: 1123-40.
- De Giogio LA, Orlandini F, Malasoma P, Zappa A. Doubleblind, crossover study of Lercanidipine versus Amlodipine in the treatment of mild-to-moderate essential hypertension. Curr Ther Res 1999; 60: 511-20.
- Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of Lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release Nifedipine. J Cardiovasc Pharmacol 1997; 29 Suppl 2: S31-5.
- Rengo F, Romis L. Activity of Lercanidipine in doubleblind comparison with Nitrendipine in combination treatment of patients with resistant essential hypertension,. J Cardiovasc Pharmacol 1997; 29 Suppl 2: S54-8.
- Leonetti G. The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: Current experience with Lercanidipine. High Blood Press 1999; 8:92-101.
- Specchia G, Saccaggi SP, Chezzi C. Cardiovascular safety of lercanidipine in patients with angina pectoris: a review of six randomized clinical trials. Curr Ther Res Clin Exp 2001; 62: 3-15.
- Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
- Fogari R, Malamani GD, Zolpi A, et al. Comparative effects of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients; a double-blind, randomized, parallel-group study. Curr Ther Res Clin Exp 2001; 61: 850-62.
- Mann RD, Mackay F, Pearce G, Freemantle S, Wilton LV. Losartan: a study of pharmacovigilance data on 14,522 patients. J Hum Hypertens 1999; 13: 551-7.
- Benson K, Harte AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878-86.
- Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-92.
- Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
- Mancia G, Omboni S, Zanchetti A. Clinical advantages of lipophilic dihydropyridines. Blood Press 1998; 7 Suppl 2: 23-6.
- Caflero M, Giasi M. Long-term (12-month) treatment with Lercanidipine in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1997; 29 Suppl 2: S45-9.
- Ninci MA, Magliocca R, Malliani A. Efficacy and tolerability of Lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, doubleblind study. J Cardiovasc Pharmacol 1997; 29 Suppl 2: S41-5.
Blood Pressure
Volume 11, 2002 - Issue 2